Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Leukemia ; 16(8): 1528-34, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12145694

ABSTRACT

Aberrant expression and activating mutations of the class III receptor tyrosine kinase Flt3 (Flk-2, STK-1) have been linked to poor prognosis in acute myeloid leukemia (AML). Inhibitors of Flt3 tyrosine kinase activity are, therefore, of interest as potential therapeutic compounds. We previously described bis(1H-2-indolyl)-1-methanones as a novel class of selective inhibitors for platelet-derived growth factor receptors (PDGFR). Several bis(1H-2-indolyl)-1-methanone derivatives, represented by the compounds D-64406 and D-65476, are also potent inhibitors of Flt3. They inhibit proliferation of TEL-Flt3-transfected BA/F3 cells with IC(50) values of 0.2-0.3 microM in the absence of IL-3 but >10 microM in the presence of IL-3. Ligand-stimulated autophosphorylation of Flt3 in EOL-1 cells and corresponding downstream activation of Akt/PKB are effectively inhibited by bis(1H-2-indolyl)-1-methanones whereas autophosphorylation of c-Kit/SCF receptor or c-Fms/CSF-1 receptor is less sensitive or insensitive, respectively. Flt3 kinase purified by different methods is potently inhibited in vitro, demonstrating a direct mechanism of inhibition. 32D cells, expressing a constitutively active Flt3 variant with internal tandem duplication are greatly sensitized to radiation-induced apoptosis in the presence of D-64406 or D-65476 in the absence but not in the presence of IL-3. Thus, bis(1H-2-indolyl)-1-methanones are potential candidates for the treatment of Flt3-driven leukemias.


Subject(s)
Enzyme Inhibitors/pharmacology , Hematopoietic Stem Cells/enzymology , Indoles/pharmacology , Protein Serine-Threonine Kinases , Proto-Oncogene Proteins/antagonists & inhibitors , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Animals , Antineoplastic Agents/pharmacology , Becaplermin , Cell Line, Transformed/drug effects , Cell Line, Transformed/enzymology , Drug Screening Assays, Antitumor , Hematopoietic Stem Cells/drug effects , Interleukin-3/pharmacology , Mice , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/enzymology , Oncogene Proteins, Fusion/antagonists & inhibitors , Phosphorylation/drug effects , Platelet-Derived Growth Factor/pharmacology , Protein Processing, Post-Translational/drug effects , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Proto-Oncogene Proteins c-kit/metabolism , Proto-Oncogene Proteins c-sis , Receptor, Macrophage Colony-Stimulating Factor/metabolism , Receptor, Platelet-Derived Growth Factor beta/genetics , Recombinant Fusion Proteins/antagonists & inhibitors , Signal Transduction/drug effects , Transfection , fms-Like Tyrosine Kinase 3
2.
Clin Cancer Res ; 7(1): 51-7, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11205918

ABSTRACT

The reduction of residual tumor cells is one of the main targets of leukapheresis product (LP) processing. Immunomagnetic enrichment/selection of CD34+ progenitor cells (Baxter Isolex 300i) can achieve a reduction of contaminating B-cells of approximately 2-3 logs in B-cell non-Hodgkin's lymphoma patients. Specific release of the enriched CD34+ cells (stem cell releasing agent PR34+; Baxter) and the use of antibody-coated immunobeads targeted against B-cell markers (CD10, CD19, CD20, CD22, CD23, and CD37) during this procedure allows the GMP-like simultaneous capture of residual B cells within a closed system. This combination of two purging techniques enhances the B-cell depletion capacity up to 4.5 logs. By performing 10 clinical-scale purging procedures, we could show that the simultaneous immunomagnetic purging method is easy to perform and highly efficient. We evaluated B-cell log depletion by flow cytometry for cases with marker-positive cells detectable before and after the purging procedure. The mean reduction of B-cells in these cases was 3.5 logs; the mean CD34+ cell yield and purity were 47 and 92%. Using three LPs, we tested the procedure on a modified Baxter Isolex 300i device with software adaptations for this procedure (software version 2.0) in direct comparison with CD34+ cell selection only, using the former version (version 1.12). The CD34+ cell yield was 49% (40-54%) for the CD34+ cell selection and 51% (19-72%) for simultaneous double selection. The mean purity was 96% for CD34+ cell selection and 98% for simultaneous double selection. B-cell depletion was 1.9 logs for CD34+ cell selection, and after simultaneous double selection, the B-cell content was decreased by 3.7 log steps (P = 0.0495). Clinical application of double-purged cells has not prolonged the hematopoietic recovery times after high-dose therapy as compared with nonpurged peripheral blood progenitor cell autotransplants. In conclusion, we could show that the simultaneous double selection protocol developed leads to a highly increased B-cell purging efficacy when compared with CD34+ cell selection without any negative effects regarding CD34+ cell yield and engraftment times after high-dose therapy.


Subject(s)
Antigens, CD34/immunology , B-Lymphocytes/immunology , Lymphocyte Depletion , Lymphoma, B-Cell/immunology , Stem Cells/immunology , Cell Survival/physiology , Disease-Free Survival , Flow Cytometry , Humans , Immunomagnetic Separation/methods , Leukapheresis/methods , Treatment Outcome
3.
Blood ; 96(12): 3907-14, 2000 Dec 01.
Article in English | MEDLINE | ID: mdl-11090077

ABSTRACT

Somatic mutations of the receptor tyrosine kinase Flt3 consisting of internal tandem duplications (ITD) occur in 20% of patients with acute myeloid leukemia. They are associated with a poor prognosis of the disease. In this study, we characterized the oncogenic potential and signaling properties of Flt3 mutations. We constructed chimeric molecules that consisted of the murine Flt3 backbone and a 510-base pair human Flt3 fragment, which contained either 4 different ITD mutants or the wild-type coding sequence. Flt3 isoforms containing ITD mutations (Flt3-ITD) induced factor-independent growth and resistance to radiation-induced apoptosis in 32D cells. Cells containing Flt3-ITD, but not those containing wild-type Flt3 (Flt3-WT), formed colonies in methylcellulose. Injection of 32D/Flt3-ITD induced rapid development of a leukemia-type disease in syngeneic mice. Flt3-ITD mutations exhibited constitutive autophosphorylation of the immature form of the Flt3 receptor. Analysis of the involved signal transduction pathways revealed that Flt3-ITD only slightly activated the MAP kinases Erk1 and 2 and the protein kinase B (Akt) in the absence of ligand and retained ligand-induced activation of these enzymes. However, Flt3-ITD led to strong factor-independent activation of STAT5. The relative importance of the STAT5 and Ras pathways for ITD-induced colony formation was assessed by transfection of dominant negative (dn) forms of these proteins: transfection of dnSTAT5 inhibited colony formation by 50%. Despite its weak constitutive activation by Flt3-ITD, dnRas also strongly inhibited Flt3-ITD-mediated colony formation. Taken together, Flt3-ITD mutations induce factor-independent growth and leukemogenesis of 32D cells that are mediated by the Ras and STAT5 pathways. (Blood. 2000;96:3907-3914)


Subject(s)
Cell Transformation, Neoplastic/drug effects , Leukemia, Myeloid/physiopathology , Milk Proteins , Protein Serine-Threonine Kinases , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/pharmacology , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/pharmacology , Acute Disease , Animals , Apoptosis/drug effects , Apoptosis/radiation effects , Cell Division/drug effects , Clone Cells/cytology , DNA Replication/drug effects , DNA-Binding Proteins/metabolism , DNA-Binding Proteins/physiology , Female , Humans , Leukemia, Myeloid/genetics , Mice , Mice, Inbred C3H , Mitogen-Activated Protein Kinase Kinases/metabolism , Mutation , Myeloid Cells/drug effects , Myeloid Cells/physiology , Neoplasms, Experimental/mortality , Neoplasms, Experimental/pathology , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Receptor Protein-Tyrosine Kinases/metabolism , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Recombinant Fusion Proteins/pharmacology , STAT5 Transcription Factor , Signal Transduction/drug effects , Tandem Repeat Sequences/genetics , Trans-Activators/metabolism , Trans-Activators/physiology , Transfection , Tumor Cells, Cultured , fms-Like Tyrosine Kinase 3 , ras Proteins/metabolism , ras Proteins/physiology
4.
Br J Haematol ; 110(3): 563-72, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10997965

ABSTRACT

The chemokine stromal cell-derived factor-1 (SDF-1) that is released by bone marrow (BM) stromal cells and contributes to stem cell homing may also play a role in the trafficking of leukaemic cells. We analysed SDF-1-induced intracellular calcium fluxes in leukaemic blasts from the peripheral blood of patients with newly diagnosed acute myeloid leukaemia (AML) and lymphoblastic leukaemia (B-lineage ALL), determined the effect of BM stromal cell-conditioned medium on in vitro transendothelial migration (TM) and measured expression of the SDF-1 receptor, CXCR4, by flow cytometry. AML FAB M1/2 blasts did not show calcium fluxes and TM was not stimulated. In myelomonocytic AML (M4/5), however, SDF-1 induced significant calcium fluxes and TM was increased twofold by the conditioned medium. M3 and M4 blasts with eosinophilia (M4eo) showed intermediate activity and M6 blasts showed no functional activity. In ALL, strong calcium fluxes and increased TM (2.5-fold) were observed. Accordingly, expression of CXCR4 was low in undifferentiated (M0) AML, myeloid (M1/2) AML and erythroid (M6) AML, but high [mean fluorescence (MF) > 50] in promyelocytic (M3) AML, myelomonocytic (M4/5) AML and B-lineage ALL. We conclude that, in AML, SDF-1 is preferentially active in myelomonocytic blasts as a result of differentiation-related expression of CXCR4. Functional activity of SDF-1 and high expression of CXCR4 in B-lineage ALL is in accordance with the previously described activity of SDF-1 in early B cells. SDF-1 may contribute to leukaemic marrow infiltration, as suggested by increased CXCR4 expression and migratory response in BM-derived blasts compared with circulating cells.


Subject(s)
Chemokines, CXC/pharmacology , Leukemia, Myelomonocytic, Acute/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Receptors, CXCR4/metabolism , Adolescent , Adult , Aged , Calcium/metabolism , Cell Movement/drug effects , Cells, Cultured , Chemokine CXCL12 , Female , Humans , Male , Middle Aged
5.
Exp Hematol ; 28(3): 335-46, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10720698

ABSTRACT

OBJECTIVE: The additional transplantation of ex vivo-generated megakaryocytic cells might enable the clinician to ameliorate or abrogate high-dose chemotherapy-induced thrombocytopenia. Therefore, the ex vivo expansion of CD34(+) PBPC was systematically studied aiming for an optimum production of megakaryocytic cells. MATERIALS AND METHODS: CD34(+) PBPC were cultured in serum-free medium comparing different (n = 23) combinations of stem cell factor (SCF) (S), IL-1beta (1), IL-3 (3), IL-6 (6), erythropoietin (EPO) (E), thrombopoietin (TPO) (T) and promegapoietin (PMP, a novel chimeric IL-3/TPO receptor agonist). Ex vivo-generated cells were assessed by flow cytometry, morphology, and progenitor cell assays. RESULTS: Addition of TPO to cultures stimulated with S163E, a potent progenitor cell expansion cocktail previously described by our group, effectively induced the generation of CD61(+) cells (day 12: 31.4 +/- 7.9%). The addition of PMP tended to be more effective than TPO +/- IL-3. Whereas EPO was not required to maximize TPO- or PMP-induced megakaryocytic cell production, the use of IL-6 and IL-1beta augmented cellular expansion as well as CD61(+) cell production rates in the majority of cytokine combinations studied. Thus, the most effective CD61(+) cell expansion cocktail consisted of S163 + PMP which resulted in 65.9 +/- 3.0% CD61(+) at day 12 and an overall production of 40.7 +/- 4.5 CD61(+) cells per seeded CD34(+) PBPC. However, the basic 2-factor combination S + PMP also allowed for an effective CD61(+) cell production (day 12 CD61(+) cell production: 15.1 +/- 1.6). Moreover, maximum amplification of CFU-Meg was observed after 7 days using this two-factor cocktail (12.9 +/- 2.6-fold). The majority of CD61(+) cells generated in TPO- or PMP-based medium were low-ploidy 4N and 8N cells, and ex vivo-generated CD61(+), CD41(+), and CD42b(+) cells were mainly double positive for FACS-measured intracellular von Willebrand Factor (vWF) (76.7 +/- 3.3%, 58.8 +/- 4.4%, and 82.7 +/- 2.5%, respectively). CONCLUSIONS: Taken together, this study demonstrates that megakaryocytic cells can be effectively produced ex vivo with as little as two-factors (SCF + PMP), an approach that might be favorably employed in a clinical expansion trial aiming to ameliorate high-dose chemotherapy-induced thrombocytopenia.


Subject(s)
Glycoproteins/pharmacology , Growth Substances/pharmacology , Hematopoiesis , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cells/pathology , Megakaryocytes/pathology , Stem Cell Factor/pharmacology , Thrombopoietin , Cell Differentiation/drug effects , Cells, Cultured , Humans
6.
Br J Haematol ; 108(2): 322-30, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10691863

ABSTRACT

The receptor tyrosine kinase Flt3 is expressed on leukaemic blasts of most cases with acute myeloid leukaemia (AML). In order to evaluate the presence and significance of constitutive activation of Flt3 for leukaemogenesis, we (1) analysed the expression and activation status of the receptor in AML blasts; and (2) evaluated the functional consequences of constitutively active Flt3 in a myeloid progenitor cell line. Immunoprecipitation studies revealed Flt3 expression in a high proportion of AML cases (27/32) with ligand-dependent Flt3 autophosphorylation in 18, constitutive autophosphorylation in three and no autophosphorylation in six cases. Only one out of three samples with constitutively active Flt3 but 3/18 samples with ligand-dependent autophosphorylated Flt3 contained the recently described internal tandem repeat (ITR) mutations. To test the significance of Flt3 activation in myeloid cell function, we also characterized the biochemical and biological effects of the activating mutation D838V of Flt3 (FLt3D838V) on the factor-dependent myeloid progenitor cell line 32Dcl3: cells transfected with wild-type Flt3 (32D/Flt3) grew FLt3 ligand (FL) dependent, and the receptor was ligand dependently autophosphorylated. In contrast, the receptor was constitutively autophosphorylated in 32D/Flt3D838V cells, which grew independently of FL. We conclude that, in some AML samples, Flt3 is constitutively activated and that this does not correlate with ITR mutations in the juxtamembrane domain. Furthermore, constitutively active Flt3 confers factor independence to the myeloid progenitor cell line 32D. It remains to be determined whether activation of Flt3 is leukaemogenic in vivo and whether strategies aimed at inhibition of Flt3 activation could inhibit leukaemogenesis.


Subject(s)
Leukemia, Myeloid/metabolism , Membrane Proteins/metabolism , Mutation/genetics , Acute Disease , Cell Division , DNA, Complementary/analysis , Gene Transfer Techniques , Humans , Leukemia, Myeloid/genetics , Leukemia, Myeloid/pathology , Neoplastic Stem Cells , Phosphorylation , Reverse Transcriptase Polymerase Chain Reaction/methods , Sequence Analysis, Protein , Tandem Repeat Sequences/genetics , Tumor Cells, Cultured
7.
Semin Hematol ; 35(3): 232-40, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9685169

ABSTRACT

The development of efficient stem and progenitor cell selection methods in combination with the development of hematopoietic growth factors facilitated the development of ex vivo expansion techniques. Currently, this novel domain of cellular therapy aims to generate stem and progenitor cells, as well as more differentiated post-progenitor cells and antigen-presenting dendritic cells. The feasibility of generating and transplanting hematopoietic progenitor cells ex vivo (using various cytokine combinations) has been successfully shown preclinically as well as clinically. Furthermore, cytokines (eg, Flt-3-ligand; thrombopoietin) have been identified that play important roles with regard to amplification of undifferentiated early hematopoietic cells. The use of lineage-specific cytokines such as granulocyte colony-stimulating factor and thrombopoietin facilitated the generation of large numbers of myeloid and megakaryocytic post-progenitor cells. The clinical usefulness of such ex vivo generated cells, however, has not yet been convincingly shown. Last, ex vivo expansion techniques can be used to generate large numbers of antigen-presenting dendritic cells from CD34+ peripheral blood progenitor cells that might be ideally used for immunotherapeutic approaches.


Subject(s)
Hematopoietic Stem Cells/cytology , Cell Count , Hematopoietic Cell Growth Factors , Hematopoietic Stem Cell Transplantation , Humans , Megakaryocytes/cytology , Thrombopoietin
9.
J Infect Dis ; 176(3): 825-8, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9291345

ABSTRACT

Plasma concentrations of interleukin-6 (IL-6) and its soluble receptor (sIL-6R) were serially determined in 32 patients with acute myeloid leukemia who developed severe sepsis (n = 19) or septic shock (n = 13) during chemotherapy-induced leukocytopenia (< or = 1 x 10(9)/L). Starting within 2 h of fever onset, IL-6 levels rose significantly over baseline in both groups to markedly higher levels in patients with evolving septic shock (medians: 372 vs. 3671 pg/mL; P < .001). Simultaneously, sIL-6R significantly decreased to lower levels in shock patients than in septic patients without hypotension (53 vs. 93 ng/mL; P = .02). This pattern was maintained throughout the observation period of up to 6 days. In patients with fatal sepsis, peak IL-6 levels were significantly higher than in survivors (P < .001), whereas minimum sIL-6R levels were markedly lower (P = .003). The reciprocal changes in circulating IL-6 and sIL-6R suggest a role for sIL-6R in modulating the effects of IL-6 during evolving sepsis in leukocytopenic patients.


Subject(s)
Antigens, CD/blood , Interleukin-6/blood , Leukemia, Myeloid/blood , Leukopenia/blood , Receptors, Interleukin/blood , Sepsis/blood , Acute Disease , Adult , Drug-Related Side Effects and Adverse Reactions , Female , Humans , Leukemia, Myeloid/complications , Leukemia, Myeloid/drug therapy , Leukopenia/chemically induced , Leukopenia/complications , Male , Middle Aged , Receptors, Interleukin-6 , Sepsis/complications , Solubility
10.
Versicherungsmedizin ; 48(3): 80-5, 1996 Jun 01.
Article in German | MEDLINE | ID: mdl-8737543

ABSTRACT

Today transplantation of different vital organs is an often and successfully applied clinical method. After organ transplantation the degree of recovery mainly depends on graft function. Besides social, work and school reintegration as well as the development of independence and self-responsibility are decisive for a general recovery. Therefore a rehabilitation should be planned in the scope of the medical care after transplantation. For this reason the rehabilitation center for children and juvenile was founded in Stronach, Austria in 1992. Since then until March 1995 136 kidney- and 54 liver transplanted patients have been treated. There is a significant increase of hemoglobine in all cases and a significant decrease of creatinine as a parameter of graft function in kidney-transplanted patients. By spiroergometric testing the heartrate at the aerobic-anaerobic threshold can be easily estimated in children and juvenile and in consideration of these results the physical endurance can be distinctively increased by an individual training program.


Subject(s)
Organ Transplantation/rehabilitation , Patient Care Team , Postoperative Complications/rehabilitation , Rehabilitation Centers , Adolescent , Austria , Child , Child, Preschool , Combined Modality Therapy , Education, Special , Female , Humans , Infant , Kidney Transplantation/rehabilitation , Liver Transplantation/rehabilitation , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...